UPDATE: Goldman Sachs Downgrades Johnson & Johnson to $63.13

According to Goldman Sachs, Johnson & Johnson JNJ is downgraded to Neutral. Goldman Sachs said that it is downgrading JNJ to Neutral from Buy as it recalibrates its ratings across its now broadened universe, which now includes Generics. “We see a total return of 19% for JNJ vs. 22% for BMY (which we are upgrading to Buy) and 25% for Buy-rated PFE. Since being added to the Americas Buy List on May 11, 2011, shares of JNJ are down 5.2% vs. the S&P 500 down 13.1%.” Johnson & Johnson closed yesterday at $63.13.